Lomaira is intended to help obese and overweight patients lose weight. The drug contains phentermine hydrochloride — an appetite suppressor — in a low dose form, which allows patients to take the drug up to three times a day before meals.
Eligible patients will pay no more than 50 cents per tablet through KVK Tech’s Lomaira Lo-Cost Access Program.
Newtown, Pa.-based KVK Tech plans to launch Lomaira by the end of September.
More articles on supply chain:
Valeant defends drug discount program for two heart drugs
Jimmy Kimmel’s EpiPen joke calls out high drug prices at Emmys
4 things to know about generic price spikes
